PAM Pathway
Overactivation of the PAM (PI3K/AKT/mTOR) pathway plays a key role in the progression of a wide variety of human cancers.
REVTORPYK™ (gedatolisib) is FDA-approved as a 2nd-line treatment for HR+/HER2-PIK3CA wild-type advanced breast cancer.
Our Pipeline
We are evaluating gedatolisib across a range of solid tumors to improve patient outcomes.
Clinical Trials